- Shi, GQ; Dropinski, JF; Zhang, Y; Santini, C; Sahoo, SP; Berger, JP; Macnaul, KL; Zhou, G; Agrawal, A; Alvaro, R; Cai, TQ; Hernandez, M; Wright, SD; Moller, DE; Heck, JV; Meinke, PT J Med Chem 48: 5589-99 (2005)
- Leite, FHA; Froes, TQ; da Silva, SG; de Souza, EIM; Vital-Fujii, DG; Trossini, GHG; Pita, SSDR; Castilho, MS Eur J Med Chem 132: 322-332 (2017)
- Wan, ZY; Yao, J; Mao, TQ; Wang, XL; Wang, HF; Chen, WX; Yin, H; Chen, FE; De Clercq, E; Daelemans, D; Pannecouque, C Eur J Med Chem 102: 215-22 (2015)
- Fookes, CJ; Pham, TQ; Mattner, F; Greguric, I; Loc'h, C; Liu, X; Berghofer, P; Shepherd, R; Gregoire, MC; Katsifis, A J Med Chem 51: 3700-12 (2008)
- Wang, YT; Shi, TQ; Fu, J; Zhu, HL Eur J Med Chem 171: 209-220 (2019)
- Shaw, SJ; Goff, DA; Carroll, DC; Singh, R; Sweeny, DJ; Park, G; Jenkins, Y; Markovtsov, V; Sun, TQ; Issakani, SD; Hitoshi, Y; Payan, DG Bioorg Med Chem 71: (2022)
- Fang, Z; Wang, TQ; Li, H; Zhang, G; Wu, XA; Yang, L; Peng, YL; Zou, J; Li, LL; Xiang, R; Yang, SY Bioorg Med Chem Lett 27: 3201-3204 (2017)
- Li, ZH; Ma, JL; Liu, GZ; Zhang, XH; Qin, TT; Ren, WH; Zhao, TQ; Chen, XH; Zhang, ZQ Eur J Med Chem 187: (2020)
- IRAK4 Enzyme Assay The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound concentration response curves, with a top concentration of 1 μM or 10 μM, were generated from 10 mM stocks of compound solubilized in DMSO using an Echo 655 (Labcyte Inc) and added to 384 well assay plates (Greiner #781280). To the assay plates, 10 μL of human recombinant IRAK4 protein (Life Technologies #PV4002) diluted to a final concentration of 0.2 nM in assay buffer (50 mM Tris-HCl pH 7.4, 10 mM MgCl, 5 mM glutathione, 0.01% BSA, 3 mM ATP) was added. The enzyme was incubated with the compounds at room temperature for 15 minutes before a peptide substrate (KKARFSRFAGSSPSQSSMVAR, Innovagen custom synthesis, 10 mM in DMSO) was added to each well to a final concentration of 10 μM using an Echo 655 (Labcyte Inc). After two hours at room temperature, the reaction was stopped with 90 μL of 0.4% formic acid (Merck #33015). The unphosphorylated and phosphorylated peptide were measured by LC-MS/MS on a Waters TQ-S mass spectrometer. Peaks were integrated using the TargetLynx software and the ratios between phosphorylated and unphosphorylated peptides were calculated.
- Potency of IRAK4 Inhibitor Compounds in IRAK4 Enzyme Assay The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound concentration response curves, with a top concentration of 1 μM or 10 μM, were generated from 10 mM stocks of compound solubilized in DMSO using an Echo 655 (Labcyte Inc) and added to 384 well assay plates (Greiner #781280). To the assay plates, 10 μL of human recombinant IRAK4 protein (Life Technologies #PV4002) diluted to a final concentration of 0.2 nM in assay buffer (50 mM Tris-HCl pH 7.4, 10 mM MgCl, 5 mM glutathione, 0.01% BSA, 3 mM ATP) was added. The enzyme was incubated with the compounds at room temperature for 15 minutes before a peptide substrate (KKARFSRFAGSSPSQSSMVAR, Innovagen custom synthesis, 10 mM in DMSO) was added to each well to a final concentration of 10 μM using an Echo 655 (Labcyte Inc). After two hours at room temperature, the reaction was stopped with 65 μL of 0.4% formic acid (Merck #33015). The unphosphorylated and phosphorylated peptide were measured by LC-MS/MS on a Waters TQ-S mass spectrometer. Peaks were integrated using the TargetLynx software and the ratios between phosphorylated and unphosphorylated peptides were calculated.
- Potency of IRAK4 Inhibitor Compounds in IRAK4 Enzyme Assay The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound concentration response curves, with a top concentration of 1 μM or 10 μM, were generated from 10 mM stocks of compound solubilized in DMSO using an Echo 655 (Labcyte Inc) and added to 384 well assay plates (Greiner #781280). To the assay plates, 10 μL of human recombinant IRAK4 protein (Life Technologies #PV4002) diluted to a final concentration of 0.2 nM in assay buffer (50 mM Tris-HCl pH 7.4, 10 mM MgCl, 5 mM glutathione, 0.01% BSA, 3 mM ATP) was added. The enzyme was incubated with the compounds at room temperature for 15 minutes before a peptide substrate (KKARFSRFAGSSPSQSSMVAR, Innovagen custom synthesis, 10 mM in DMSO) was added to each well to a final concentration of 10 μM using an Echo 655 (Labcyte Inc). After two hours at room temperature, the reaction was stopped with 90 μL of 0.4% formic acid (Merck #33015). The unphosphorylated and phosphorylated peptide were measured by LC-MS/MS on a Waters TQ-S mass spectrometer. Peaks were integrated using the TargetLynx software and the ratios between phosphorylated and unphosphorylated peptides were calculated.